Denali Therapeutics Cash from Investing (Quarterly) Trends

Denali Therapeutics Inc (DNLI)

20.13 -0.38 (-1.85%) USD | NASDAQ | May 20, 16:00

20.12 -0.01 (-0.05%) After-Hours: 20:00

Cash from Investing (Quarterly) Chart

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2017. Upgrade now.

Date	Value
March 31, 2024	-453.19M
December 31, 2023	73.05M
September 30, 2023	100.91M
June 30, 2023	168.07M
March 31, 2023	-92.72M
December 31, 2022	-127.56M
September 30, 2022	15.42M
June 30, 2022	88.63M
March 31, 2022	-117.88M
December 31, 2021	-40.75M
September 30, 2021	-53.01M
June 30, 2021	97.54M
March 31, 2021	-25.40M
December 31, 2020	-367.34M
September 30, 2020	-212.12M

Date	Value
June 30, 2020	-30.41M
March 31, 2020	-13.33M
December 31, 2019	42.38M
September 30, 2019	49.49M
June 30, 2019	63.88M
March 31, 2019	-8.047M
December 31, 2018	-61.40M
September 30, 2018	44.73M
June 30, 2018	30.53M
March 31, 2018	-301.27M
December 31, 2017	-95.15M
September 30, 2017	16.53M
June 30, 2017	22.07M
March 31, 2017	15.38M

Cash From Investing Definition

Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

-453.19M

Minimum

Mar 2024

168.07M

Maximum

Jun 2023

-41.72M

Average

-19.37M

Median

Cash from Investing (Quarterly) Benchmarks

Halozyme Therapeutics Inc	-82.68M
AIM ImmunoTech Inc	-0.158M
Perspective Therapeutics Inc	-47.30M
Protalix BioTherapeutics Inc	-0.606M
Armata Pharmaceuticals Inc	-0.25M

Cash from Investing (Quarterly) Related Metrics

Cash from Operations (Quarterly)	-113.62M
Cash from Financing (Quarterly)	500.28M
Free Cash Flow	-425.11M
Free Cash Flow Per Share (Quarterly)	-0.7749
Free Cash Flow Yield	-14.92%